Clinical Trial

Platelet Aggregation in the Diagnosis of Acute Graft Rejection

Recruiting
View on ClinicalTrials.gov →
Summary
The study titled "Platelet Aggregation in the Diagnosis of Acute Graft Rejection" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.
Trial Details
NCT Number NCT07275541
Lead Sponsor University Hospital, Martin
Conditions Platelet Aggregation, Kidney Transplant Rejection
Enrollment 60 participants
Start Date 2024-11-26
Primary Completion 2026-11-26 (estimated)
Study Completion 2027-11-26 (estimated)
Updated on ClinicalTrials.gov 2025-12-10